Respiratory Function Changes as Early Signs of Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis Diagnosis Muscle weakness Pulmonary function Respiratory drive

Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
2023
Historique:
received: 17 04 2023
accepted: 27 08 2023
medline: 22 11 2023
pubmed: 17 10 2023
entrez: 16 10 2023
Statut: ppublish

Résumé

The current diagnostic criteria for amyotrophic lateral sclerosis (ALS) may remain unsatisfactory for months or years in the early disease. Pulmonary assessment has never been considered useful in the early diagnosis of ALS, and studies of pulmonary function in this patient category are lacking. The objective of this study was to assess the pulmonary function in subjects with unspecific symptoms of ALS in whom an ALS diagnosis cannot be reached based on the current available guidelines. We performed pulmonary function tests, arterial gas analysis, maximal inspiratory (MIP) and expiratory (MEP) pressure, and respiratory drive (P0.1) assessment in 35 patients with unspecific neurological symptoms at the time of the visit and those were subsequently diagnosed with ALS 2 years after the initial visit ("pre-ALS"); we compared these patients with 29 patients with established ALS and with 28 control subjects. Spirometric parameters were not different between the three groups. However, MIP was significantly lower and P0.1 was significantly increased (with the ratio P0.1/MIP significantly higher) in both established and pre-ALS patients compared to controls, while both MIP and P0.1 were similar between established ALS and pre-ALS. Changes in MIP, P0.1, and P0.1/MIP ratio are highly suggestive of preclinical ALS when the spirometry and neurodiagnostic tests are still inconclusive. MIP and P0.1 are noninvasive measurements that can be easily assessed in an ambulatory setting. Future studies on larger cohorts are needed to validate the use of these parameters in the preclinical diagnosis of ALS as well as in other neuromuscular diseases.

Sections du résumé

BACKGROUND BACKGROUND
The current diagnostic criteria for amyotrophic lateral sclerosis (ALS) may remain unsatisfactory for months or years in the early disease. Pulmonary assessment has never been considered useful in the early diagnosis of ALS, and studies of pulmonary function in this patient category are lacking.
OBJECTIVES OBJECTIVE
The objective of this study was to assess the pulmonary function in subjects with unspecific symptoms of ALS in whom an ALS diagnosis cannot be reached based on the current available guidelines.
METHODS METHODS
We performed pulmonary function tests, arterial gas analysis, maximal inspiratory (MIP) and expiratory (MEP) pressure, and respiratory drive (P0.1) assessment in 35 patients with unspecific neurological symptoms at the time of the visit and those were subsequently diagnosed with ALS 2 years after the initial visit ("pre-ALS"); we compared these patients with 29 patients with established ALS and with 28 control subjects.
RESULTS RESULTS
Spirometric parameters were not different between the three groups. However, MIP was significantly lower and P0.1 was significantly increased (with the ratio P0.1/MIP significantly higher) in both established and pre-ALS patients compared to controls, while both MIP and P0.1 were similar between established ALS and pre-ALS.
CONCLUSIONS CONCLUSIONS
Changes in MIP, P0.1, and P0.1/MIP ratio are highly suggestive of preclinical ALS when the spirometry and neurodiagnostic tests are still inconclusive. MIP and P0.1 are noninvasive measurements that can be easily assessed in an ambulatory setting. Future studies on larger cohorts are needed to validate the use of these parameters in the preclinical diagnosis of ALS as well as in other neuromuscular diseases.

Identifiants

pubmed: 37844546
pii: 000533870
doi: 10.1159/000533870
doi:

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

919-923

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Mario Polverino (M)

Lung Division, Department of Medicine, "M. Scarlato" Hospital, Scafati, Italy.
Nefrocenter Research S.c.arl, Cava de' Tirreni, Italy.

Simone Sampaolo (S)

Neurologic Division, Department of Medicine, University of Campania "L. Vanvitelli", Naples, Italy.

Antonio Capuozzo (A)

Lung Division, Department of Medicine, "M. Scarlato" Hospital, Scafati, Italy.

Marco Fasolino (M)

Lung Division, Department of Medicine, "M. Scarlato" Hospital, Scafati, Italy.

Michele Aliberti (M)

Neurologic Division, Department of Medicine, "Umberto I" Hospital, Nocera Inferiore, Italy.

Ersilia Satta (E)

Nefrocenter Research S.c.arl, Cava de' Tirreni, Italy.

Carlo Santoriello (C)

Lung Division, Department of Onco-Hematology and Pneumology, AORN "Cardarelli", Naples, Italy.

James Peter Orengo (JP)

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Francesca Polverino (F)

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH